MedTrace Logo

Effects of Second-generation Antihistamine Bepotastine on Cough Outcomes in Cough Patients With Allergic Rhinitis

NCT04877678 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-01-05

No results posted yet for this study

Summary

This is a phase 4 study to evaluate the the efficacy of second generation antihistamine on cough outcomes in cough patients with allergic rhinitis.

Conditions

  • Allergic Rhinitis
  • Cough

Interventions

DRUG

Bepotastine

10 mg Bepotastine, twice a day

DRUG

Placebo

Identical looking placebo, twice a day

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Woo-Jung Song · Asan Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2022-09-01
Completion
2022-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04877678 on ClinicalTrials.gov